Loading...
Market
Will Wave Life Sciences announce a new pharma partnership by March 31, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Wave Life Sciences or the partner company
Story
Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO
Oct 16, 2024, 08:55 AM
Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Announces new clinical trial • 25%
Announces new partnership • 25%
Announces new funding • 25%
No significant announcements • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
New clinical trial phase announced • 25%
New therapeutic indication announced • 25%
No major announcements • 25%
Other significant announcements • 25%
